Research and Clinical Trials

Title  

COG AHOD1331: A Randomized Phase III Study of Brentuximab Vedotin (SGN-35, IND #117117) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents

Brief Description  

1.1 Primary Aims 1.1.1 To assess the event free survival (EFS) of a novel regimen incorporating brentuximab vedotin (Bv; AdcetrisTM) in the chemotherapy backbone of doxorubicin (Adriamycin), vincristine, etoposide, prednisone and cyclophosphamide (Bv-AVEPC) in newly diagnosed high-risk cHL compared to those treated with ABVE-PC.

Who may be Eligible  

Please contact us for eligibility criteria.

Speciality/Disorder  

Hodgkin's Lymphoma

Status  

OPEN

Start Date  

12/22/2015

IRB Number  

00012160

Principal Investigator  

Kaplan, Joel Adam

Contact Name  

Sceria Jenkins

For More Information, Contact  Sceria  , Jenkins
Phone:  980-442-2323 Fax:    
Email:  sceria.jenkins@atriumhealth.org
Address:1021 Morehead Medical Drive Suite 2200 Charlotte, 28204